JP Morgan Maintains Overweight on Olema Pharmaceuticals, Raises Price Target to $16
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Anupam Rama maintains an Overweight rating on Olema Pharmaceuticals (NASDAQ:OLMA) and raises the price target from $14 to $16.
August 10, 2023 | 4:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Olema Pharmaceuticals and raises the price target from $14 to $16.
The news is directly related to Olema Pharmaceuticals. JP Morgan's decision to maintain an Overweight rating and raise the price target indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100